BTK and cancer: Notably, data related to anti-cancer agents belonging to interleukin (IL) inhibitors, immunomodulators, androgen biosynthesis inhibitors, complement system inhibitors, immune checkpoint inhibitors, bruton tyrosine kinase inhibitors, and Janus-associated kinase (JAK) inhibitors currently under trials for the treatment of COVID-19 are available.